{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Reference+product&page=16", "query": { "intervention": "Reference product", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 362, "total_pages": 37, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Reference+product&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Reference+product&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-02T05:50:19.282Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05077969", "title": "Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "2019 Novel Coronavirus Disease", "2019 Novel Coronavirus Infection", "2019-nCoV Disease", "2019-nCoV Infection", "COVID-19", "COVID-19 Pandemic", "COVID-19 Virus Disease", "COVID-19 Virus Infection", "Covid19", "Coronavirus Disease 2019", "SARS-CoV2 Infection", "SARS-CoV-2 Acute Respiratory Disease" ], "interventions": [ { "name": "Famotidine", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Leidos Life Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2021-12-29", "completion_date": "2022-07-08", "has_results": true, "last_update_posted_date": "2024-07-09", "last_synced_at": "2026-11-02T05:50:19.282Z", "location_count": 15, "location_summary": "Newport Beach, California • Miami, Florida • Atlanta, Georgia + 12 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Hazlehurst", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05077969" }, { "nct_id": "NCT03499873", "title": "Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cataract" ], "interventions": [ { "name": "Nepafenac 0.3% Oph Susp", "type": "DRUG" }, { "name": "Placebos", "type": "DRUG" }, { "name": "Nepafenac 0.3% Oph Susp (reference)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Actavis Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 448, "start_date": "2018-03-28", "completion_date": "2018-12-18", "has_results": true, "last_update_posted_date": "2021-02-16", "last_synced_at": "2026-11-02T05:50:19.282Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03499873" }, { "nct_id": "NCT04358770", "title": "Bio-equivalence Vasoconstriction Activity Study for Topically Applied Clocortolone Pivalate 0.1% Cream", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bioequivalence Study" ], "interventions": [ { "name": "Clocortolone Pivalate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sun Pharmaceutical Industries, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "18 Years to 35 Years" }, "enrollment_count": 124, "start_date": "2018-03-02", "completion_date": "2018-05-11", "has_results": false, "last_update_posted_date": "2020-04-24", "last_synced_at": "2026-11-02T05:50:19.282Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04358770" }, { "nct_id": "NCT02267746", "title": "A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acne Vulgaris" ], "interventions": [ { "name": "Tazarotene (Fabior™)", "type": "DRUG" }, { "name": "Tazarotene (Actavis)", "type": "DRUG" }, { "name": "Vehicle foam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Actavis Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "12 Years to 40 Years" }, "enrollment_count": 893, "start_date": "2014-06", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2020-06-12", "last_synced_at": "2026-11-02T05:50:19.282Z", "location_count": 14, "location_summary": "Encino, California • Fremont, California • Brandon, Florida + 8 more", "locations": [ { "city": "Encino", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Brandon", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02267746" }, { "nct_id": "NCT03549897", "title": "Bronchoprovocation Study to Evaluate the Pharmacodynamics of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "90 mcg Reference Product", "type": "DRUG" }, { "name": "180 mcg Reference Product", "type": "DRUG" }, { "name": "90 mcg Test Product", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amneal Ireland Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 100, "start_date": "2018-03-16", "completion_date": "2018-09", "has_results": false, "last_update_posted_date": "2018-06-14", "last_synced_at": "2026-11-02T05:50:19.282Z", "location_count": 1, "location_summary": "Brookhaven, New York", "locations": [ { "city": "Brookhaven", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03549897" }, { "nct_id": "NCT02160587", "title": "Safety Study to Evaluate the Contact Sensitizing Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Surgical Site Infection" ], "interventions": [ { "name": "Chloraprep", "type": "DRUG" }, { "name": "0.9% Physiological Saline", "type": "DRUG" }, { "name": "ZuraPrep without IPA", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Zurex Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 208, "start_date": "2014-07", "completion_date": "2014-10", "has_results": false, "last_update_posted_date": "2015-03-17", "last_synced_at": "2026-11-02T05:50:19.282Z", "location_count": 1, "location_summary": "Bozeman, Montana", "locations": [ { "city": "Bozeman", "state": "Montana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02160587" }, { "nct_id": "NCT04685096", "title": "Anti-ageing Efficacy of a Cosmetic Formulation Containing NMN (2%) Versus Placebo", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Wrinkle", "Fatigue", "Puffiness Around the Eyes" ], "interventions": [ { "name": "Test product creme", "type": "OTHER" }, { "name": "Reference creme", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Seneque SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "40 Years to 65 Years · Female only" }, "enrollment_count": 89, "start_date": "2020-12-12", "completion_date": "2021-04-16", "has_results": false, "last_update_posted_date": "2021-04-23", "last_synced_at": "2026-11-02T05:50:19.282Z", "location_count": 1, "location_summary": "Piscataway, New Jersey", "locations": [ { "city": "Piscataway", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04685096" }, { "nct_id": "NCT05078827", "title": "Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Actinic Keratoses" ], "interventions": [ { "name": "Test Product (A): Fluorouracil Cream, 5% topical cream", "type": "DRUG" }, { "name": "Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A.", "type": "DRUG" }, { "name": "Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Encube Ethicals Pvt. Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 458, "start_date": "2022-03-01", "completion_date": "2022-12-01", "has_results": false, "last_update_posted_date": "2023-03-14", "last_synced_at": "2026-11-02T05:50:19.282Z", "location_count": 7, "location_summary": "Bakersfield, California • Cerritos, California • Lauderdale Lakes, Florida + 3 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Cerritos", "state": "California" }, { "city": "Lauderdale Lakes", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05078827" }, { "nct_id": "NCT02741739", "title": "Study of the Blood Concentrations of Two Formulations of REGN1033 in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "REGN1033", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 28, "start_date": "2016-03", "completion_date": "2016-05", "has_results": false, "last_update_posted_date": "2016-10-14", "last_synced_at": "2026-11-02T05:50:19.282Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02741739" }, { "nct_id": "NCT01677065", "title": "A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Healthy" ], "interventions": [ { "name": "Oxycodone controlled-release test formulation", "type": "DRUG" }, { "name": "Immediate-release reference drug", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 14, "start_date": "2012-09", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2018-09-28", "last_synced_at": "2026-11-02T05:50:19.282Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01677065" } ] }